Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.

Abstract titles reveal some of ASCO’s key datasets.

The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.

Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.

Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.

Readout of the delayed Galaxies Lung-201 study is due imminently.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.